G9pharma co., LTD reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was KRW 8,196.43 million compared to KRW 17,225.37 million a year ago. Basic loss per share from continuing operations was KRW 2,010 compared to KRW 4,957 a year ago. Basic loss per share was KRW 2,010 compared to KRW 4,957 a year ago.
For the six months, negative sales was KRW 0.00001 million. Net loss was KRW 13,322.27 million compared to KRW 24,904.87 million a year ago. Basic loss per share from continuing operations was KRW 3,266 compared to KRW 7,194 a year ago. Basic loss per share was KRW 3,266 compared to KRW 7,194 a year ago.